Holen Sie sich die Stockscreener-App
195.34
1.76%
3.39
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen stock holds steady as Alzheimer portfolio and pipeline shape the long-term story - Ad-hoc-news.de
Biogen Inc (BIIB) Shares Fall 8.2% -- What GF Score of 74 Tells Investors - GuruFocus
Biogen Inc.'s Stock Price Plummets to $191.95, Recording a Sharp 8.17% DropThe Latest Market Update - Smartkarma
Biogen (BIIB) Alzheimer’s Association International Conference (AAIC Meeting) 2026 summary - Quartr
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss - Yahoo Finance
BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study - TradingView
Biogen at aaic 2026: tau drug advances despite mixed trial readout - Investing.com
Biogen (BIIB) Reports Mixed Results on Alzheimer's Drug Diraners - GuruFocus
Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi - Yahoo! Finance Canada
Biogen Inc at Alzheimer's Association International Conference (AAIC) Transcript - GuruFocus
Why Is Biogen Stock Falling Tuesday? - Benzinga
Eisai, Biogen report real-world Alzheimer’s drug study results - Investing.com
Biogen tumbles 8.7% as breakthrough Alzheimer’s data is clouded by dosing paradox - Investing.com South Africa
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment - Biogen
Biogen drops after data for novel Alzheimer’s drug (BIIB:NASDAQ) - Seeking Alpha
Italy The AGCM Opens a Formal Investigation into Biogen for Alleged Abuse of Dominant Position in th - Bird & Bird
Biogen slides as investors reassess Alzheimer’s data and earnings overhang - Quiver Quantitative
Biogen Drops 7.7% After Morgan Stanley Maintains Equal-Weight - AlphaStreet
Biogen Shares Fall as Alzheimer’s Tau Trial Data Disappoint - Bloomberg.com
Biogen drops after additional mid-stage trial data for Ionis-partnered Alzheimer’s drug - Seeking Alpha
Biogen Shares Rise After Positive Phase 2 Alzheimer’s Trial Results (BIIB) - Yahoo Finance
Biogen reports phase 2 Alzheimer’s drug trial results - Investing.com
Biogen reports phase 2 Alzheimer’s drug trial results By Investing.com - Investing.com Canada
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease - Biogen
Biogen stock rises on positive Alzheimer’s drug trial data - Investing.com
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed - marketscreener.com
Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows - STAT
Biogen’s Diranersen Efficacy Similar To Leqembi On Key Alzheimer’s Endpoint - insights.citeline.com
Piper Sandler reiterates Biogen stock rating on Alzheimer’s drugs - Investing.com
Piper Sandler reiterates Biogen stock rating on Alzheimer’s drugs By Investing.com - Investing.com Canada
Eisai, Biogen Push Full SC Leqembi With FDA Nod As Alzheimer’s Market Competition Builds - insights.citeline.com
Is Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector? - simplywall.st
Biogen (BIIB) Receives Buy Rating with $255 Target Following Leq - GuruFocus
Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Tr - GuruFocus
A Look at Biogen Inc (BIIB) After 5.0% Gain -- GF Value $191.79 vs Price $209.03 - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MSN
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease - Biogen
Biogen Inc.’s stock price soars to $209.03, marking a bullish 4.96% surge - Smartkarma
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug - Reuters
Biogen (BIIB) Upgraded to Buy with Price Target Raised to $235 - GuruFocus
Biogen (BIIB) Sees Boost Following Early FDA Approval of Leqembi - GuruFocus
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details - Barron's
This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Biogen Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth… - marketscreener.com
Biogen Inc. (BIIB) Stock Analysis: Navigating a Robust Pipeline with 11.89% Upside Potential - DirectorsTalk Interviews
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026 - Biogen
Eisai and Biogen Present AAIC 2026 Data Supporting Comparable Efficacy and Safety of LEQEMBI Subcutaneous Autoinjector and IV Dosing in Early Alzheimer’s Disease - Quiver Quantitative
Eisai Co., Ltd. And Biogen Inc. Present Clinical Data Supporting Leqembi Subcutaneous Autoinjector Efficacy And Safety Comparable To Intravenous Formulation In Early Alzheimer's Disease - marketscreener.com
Biogen stock reflects Alzheimer portfolio repositioning as neurology pipeline gains weight - ad-hoc-news.de
AstraZeneca's $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw - finance.biggo.com
Why is Biogen stock climbing today? By Investing.com - Investing.com Canada
Why Biogen (BIIB) is poised to beat earnings estimates again - MSN
Biogen Slides as Newly Disclosed Charges Pressure Near-Term Earnings - Moomoo
BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers - Stocktwits
Biogen's Q2 2026 Earnings: What to Expect - Yahoo Finance
Maria Elvira Salazar Makes Significant Trades in Biogen, Brookfield Renewable, and Salesforce - Investing.com
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Morgan Stanley Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $222 - Moomoo
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $217 to $255 - Moomoo
BofA Securities Adjusts Biogen Price Target to $217 From $203 - marketscreener.com
Moderna adds former Biogen CFO to board of directors - Investing.com
Moderna adds former Biogen CFO to board of directors By Investing.com - Investing.com Canada
Former Biogen CFO Michael McDonnell joins Moderna (NASDAQ: MRNA) board and Audit Committee - Stock Titan
Moderna Appoints Michael McDonnell to Board of Directors - ACCESS Newswire
Moderna adds former Biogen CFO Michael McDonnell to its board - Stock Titan
Morgan Stanley Adjusts Price Target Biogen to $222 From $224, Maintains Equalweight Rating - marketscreener.com
2.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):